464 related articles for article (PubMed ID: 30971165)
1. Combination immunosuppressant therapy and lupus nephritis outcome: a hospital-based study.
Chen YM; Hung WT; Liao YW; Hsu CY; Hsieh TY; Chen HH; Hsieh CW; Lin CT; Lai KL; Tang KT; Tseng CW; Huang WN; Chen YH
Lupus; 2019 Apr; 28(5):658-666. PubMed ID: 30971165
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.
Mejía-Vilet JM; Arreola-Guerra JM; Córdova-Sánchez BM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566
[TBL] [Abstract][Full Text] [Related]
3. Renal flare prediction and prognosis in lupus nephritis Hispanic patients.
Mejía-Vilet JM; Córdova-Sánchez BM; Arreola-Guerra JM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
Lupus; 2016 Mar; 25(3):315-24. PubMed ID: 26405028
[TBL] [Abstract][Full Text] [Related]
4. Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis.
Davidson JE; Fu Q; Ji B; Rao S; Roth D; Magder LS; Petri M
J Rheumatol; 2018 May; 45(5):671-677. PubMed ID: 29496892
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of biopsy-proven lupus nephritis in Iran.
Fatemi A; Kazemi M; Sayedbonakdar Z; Farajzadegan Z; Karimzadeh H; Moosavi M
Int J Rheum Dis; 2013 Dec; 16(6):739-46. PubMed ID: 24267776
[TBL] [Abstract][Full Text] [Related]
6. Chronicity index, especially glomerular sclerosis, is the most powerful predictor of renal response following immunosuppressive treatment in patients with lupus nephritis.
Park DJ; Choi SE; Xu H; Kang JH; Lee KE; Lee JS; Choi YD; Lee SS
Int J Rheum Dis; 2018 Feb; 21(2):458-467. PubMed ID: 29314776
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis.
Rijnink EC; Teng YKO; Wilhelmus S; Almekinders M; Wolterbeek R; Cransberg K; Bruijn JA; Bajema IM
Clin J Am Soc Nephrol; 2017 May; 12(5):734-743. PubMed ID: 28473317
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
10. Remission of proteinuria indicates good prognosis in patients with diffuse proliferative lupus nephritis.
Koo HS; Kim S; Chin HJ
Lupus; 2016 Jan; 25(1):3-11. PubMed ID: 26159540
[TBL] [Abstract][Full Text] [Related]
11. A retrospective analysis of clinical presentation of lupus nephritis.
Singh S; Zhou XJ; Ahn C; Saxena R
Am J Med Sci; 2011 Dec; 342(6):467-73. PubMed ID: 21681076
[TBL] [Abstract][Full Text] [Related]
12. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
13. Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis.
Pakchotanon R; Gladman DD; Su J; Urowitz MB
Lupus; 2018 Mar; 27(3):468-474. PubMed ID: 28857717
[TBL] [Abstract][Full Text] [Related]
14. Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia.
Al Arfaj AS; Khalil N; Al Saleh S
Rheumatol Int; 2009 Jul; 29(9):1057-67. PubMed ID: 19381639
[TBL] [Abstract][Full Text] [Related]
15. Improvement of Outcomes in Patients with Lupus Nephritis: Management Evolution in Chinese Patients from 1994 to 2010.
Shao SJ; Hou JH; Xie GT; Sun W; Liang DD; Zeng CH; Zhu HX; Liu ZH
J Rheumatol; 2019 Aug; 46(8):912-919. PubMed ID: 30824650
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: a university hospital experience.
Momtaz M; Fayed A; Wadie M; Gamal SM; Ghoniem SA; Sobhy N; Kamal Elden NM; Hamza WM
Lupus; 2017 Dec; 26(14):1564-1570. PubMed ID: 28625079
[TBL] [Abstract][Full Text] [Related]
17. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.
Condon MB; Ashby D; Pepper RJ; Cook HT; Levy JB; Griffith M; Cairns TD; Lightstone L
Ann Rheum Dis; 2013 Aug; 72(8):1280-6. PubMed ID: 23740227
[TBL] [Abstract][Full Text] [Related]
18. Complete renal response at 12 months after induction therapy is associated with renal relapse-free rate in lupus nephritis: a single-center, retrospective cohort study.
Ichinose K; Kitamura M; Sato S; Eguchi M; Okamoto M; Endo Y; Tsuji S; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Koga T; Kawashiri S; Iwamoto N; Igawa T; Tamai M; Nakamura H; Origuchi T; Nishino T; Kawakami A
Lupus; 2019 Apr; 28(4):501-509. PubMed ID: 30755146
[TBL] [Abstract][Full Text] [Related]
19. Outcome of lupus nephritis in childhood onset SLE in North and Central India: single-centre experience over 25 years.
Srivastava P; Abujam B; Misra R; Lawrence A; Agarwal V; Aggarwal A
Lupus; 2016 Apr; 25(5):547-57. PubMed ID: 26637291
[TBL] [Abstract][Full Text] [Related]
20. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
